Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA), Hyperfine (HYPR) and Biogen (BIIB)
Enanta Pharmaceuticals: Hold Rating Amid RSV Pipeline Progress and Financial Caution
Buy Rating Affirmed on Enanta Pharmaceuticals' Promising Drug Pipeline and Strategic Expansion Into Immunology
JP Morgan Maintains Underweight on Enanta Pharma, Lowers Price Target to $10
Evercore ISI Sticks to Their Buy Rating for Enanta Pharmaceuticals (ENTA)
Evercore Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $30
HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $27 Price Target
H.C. Wainwright Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $27
Enanta Pharmaceuticals: Promising Pipeline Progress and a Buy Rating
JMP Securities Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $22
Buy Rating Affirmed for Enanta Pharmaceuticals Amid Promising Clinical Developments and Robust Financial Health
Hold Rating on Enanta Pharmaceuticals Amidst Clinical Trials Uncertainty and Financial Outlook
Buy Rating Affirmed for Enanta Pharmaceuticals Amidst Promising RSV Developments and Clinical Trial Execution
J.P. Morgan Securities: Maintaining the Enanta Pharma (ENTA.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $23.00 to $22.00.
Enanta Pharma Analyst Ratings
JMP Securities Maintains Market Outperform on Enanta Pharma, Lowers Price Target to $22
Analysts' Top Healthcare Picks: OrthoPediatrics (KIDS), Enanta Pharmaceuticals (ENTA)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Enanta Pharmaceuticals (ENTA), OrthoPediatrics (KIDS) and Avanos Medical (AVNS)
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating
Oppenheimer Keeps Their Hold Rating on Enanta Pharmaceuticals (ENTA)